

Upcoming Clinician Briefing

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, is pleased to invite shareholders to attend an upcoming investor webinar with Professor Russell Dale, Co-Principal Investigator for the NTI164 clinical trial in PANDAS/PANS and Professor of Paediatric Neurology, University of Sydney and Children's Hospital at Westmead. Professor Dale is an internationally recognised clinician and researcher in PANDAS/PANS research.

Neurotech Executive Director, Dr Thomas Duthy, will provide an overview and update on Neurotech followed by a presentation by Professor Dale. The interactive Webinar will provide investors with an introduction to this challenging neurological disorder, how PANDAS/PANS is diagnosed, along with treatment options and a discussion of the Phase I/II NTIPANS1 clinical trial sponsored by Neurotech. Neurotech expects the results of the clinical trial will be available in mid to late September 2023.

The webinar will be held on:

15th September 2023, 11:00am AEST/ 9:00am AWST.

This webinar can be viewed live via Zoom by registering via the link below.

https://us02web.zoom.us/webinar/register/WN_JwmlCHwSPiqfZbjYWv6vg

Following the presentation, attendees will have the opportunity to ask questions directly to Professor Dale during a moderated Q&A session. Investors are encouraged to submit questions ahead of the event directly to Matthew Wright, NWR Communications at matt@nwrcommunications.com.au. A recording of the webinar will be made available following the event.

Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS is a clinical diagnosis given to children who have a dramatic (typically within one day) onset of neuropsychiatric symptoms including intense anxiety, obsessive-compulsive disorder (OCD) and/or severely restrictive eating. Children may exhibit repetitive tic movements, become moody, irritable/aggressive, and anxious.

The cause of PANS is unknown in most cases; however, the disorder is hypothesised to be triggered by infections, metabolic disturbances, and other inflammatory reactions. The PANDAS subgroup is defined by an association with Group A *Streptococcus* infection, and specific neuropsychiatric symptoms similar to PANS. Both PANDAS and PANS are considered rare paediatric (orphan) neurological disorders.ⁱ

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors/Media:

Dr Thomas Duthy
Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC ($M < 0.3\%$) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

About PANDAS/PANS

Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, is a clinical diagnosis given to children who have a dramatic (typically within one day) onset of neuropsychiatric symptoms including Obsessive-Compulsive Disorder (OCD) and/or restrictive eating. Children may exhibit repetitive tic movements, become moody, irritable/aggressive and anxious and have difficulty with schoolwork. The cause of PANS is unknown in the majority of cases; however, the disorder is hypothesised to be triggered by infections, metabolic disturbances, and other inflammatory reactions. PANDAS is considered a subset of PANS.

About Neurotech PANDAS/PANS Phase I/II Clinical Trial

NTIPANS1 is a single-arm, open-label, Phase I/II clinical trial that will recruit 15 paediatric patients with a clinical diagnosis of moderate to severe PANDAS/PANS to determine the efficacy and safety of orally administered NTI164 in these patients. The primary endpoints of the trial are the change from baseline at twelve (12) weeks for the Revised Children's Anxiety and Depression Scale-Parent-rated (RCADS-P) score and Clinical Global Impression (CGI) of severity (CGI-S) and improvement (CGI-I). Secondary clinical endpoints include other gold-standard, validated assessment tools: Yale Global Tic Severity Scale (YGTSS), Children's Yale-Brown Obsessive-Compulsive Scale, Conners Scale and EQ-5D-Y. Other secondary endpoints will examine the Safety and Tolerability of orally administered NTI164 (at 5, 10, 15 and 20 mg/kg/day). The trial intends to enrol children at two centres within Australia; the Children's Hospital at Westmead and the Paediatric Neurology Unit at Monash Medical Centre. The Phase I/II

clinical trial has been registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number: ACTRN12622001419752 or visit: <https://www.anzctr.org.au>

ⁱ <https://rarediseases.info.nih.gov/diseases/7312/index>